Managing Hand, Foot, and Mouth Disease: Clinical and Infection Control Considerations
Implement rigorous hand hygiene protocols and contact precautions as the cornerstone of HFMD management, with particular focus on identifying high-risk children under 3 years with EV-A71 infection who require close monitoring for neurological complications.
Infection Control Priorities
Hand Hygiene - The Single Most Critical Intervention
Hand hygiene is the single most important method of preventing transmission of infectious agents 1. For HFMD cases:
- Use alcohol-based hand rub before and after each patient encounter, covering all hand surfaces until dry
- Wash with soap and water when hands are visibly soiled or contaminated with body fluids (common with HFMD given oral and skin lesions)
- Apply hand hygiene after removing gloves, between dirty and clean procedures, and after contact with the patient's environment 1
Contact Precautions and Barrier Protection
- Gloves are mandatory for contact with blood, body fluids, secretions, mucous membranes, and nonintact skin 1
- Fluid-impermeable gowns should be worn during procedures likely to generate splashes
- Isolate patients to avoid cross-infection 2
Facility-Level Control Measures
The evidence strongly supports rapid response protocols 3:
- Notify local health authorities within 24 hours of clustered outbreaks (≥5 cases)
- Delayed notification beyond 24 hours significantly extends outbreak length (4-46 days) and increases attack rates (0.97%-28.18%) 3
- Train dedicated infection control specialists in childcare facilities to serve as first-contact points 3
Clinical Risk Stratification
High-Risk Population Identification
Focus surveillance on children under 3 years old with EV-A71 infection and disease duration less than 3 days 2. This population has the highest risk of severe complications including encephalitis and neurogenic pulmonary edema.
Seven Critical Warning Signs for Deterioration
Monitor for these indicators that signal progression to severe disease 2:
- Persistent hyperthermia (unremitting high fever)
- Neurological involvement (lethargy, myoclonus, ataxia, cranial nerve palsies)
- Worsening respiratory rate and rhythm
- Circulatory dysfunction (cold limbs, prolonged capillary refill)
- Elevated peripheral WBC count
- Elevated blood glucose
- Elevated blood lactic acid
Serotype-Specific Severity
EV-A71 causes CNS complications in 40% of hospitalized cases, compared to CV-A4 (17%), CV-A2 (13%), CV-A10 (10%), CV-A6 (7%), and CV-A16 (4%) 4. However, non-EV-A71 enteroviruses collectively account for 35% of CNS complications 4, so vigilance is required regardless of serotype.
Clinical Presentation Variations
Atypical Features by Serotype
- CV-A2 and CV-A4: Less likely to have classic hand/foot/buttock rashes; more likely to present with high fever 4
- EV-A71: Fewer mouth lesions but higher neurological risk 4
- CV-A6: Can cause severe disease despite lower overall CNS complication rates 4
Non-CNS Predictors of Severe Disease
Beyond neurological signs, monitor for 4:
- Cold limbs and vomiting
- Abnormal blood globulin and platelet counts
- Altered serum chloride and neutrophil counts
Outbreak Management Timeline
Seasonal and Temporal Patterns
- Peak transmission occurs May-July 5
- Disease spreads rapidly within facilities, especially with delayed control responses 3
- Three distinct epidemic waves can occur with different enterovirus serotypes predominating 6
Geographic Spread Patterns
Transmission follows rivers and local secondary roads, likely through local trade and occupational movements 6. This informs targeted surveillance in high-traffic areas.
Treatment Approach
Mild Cases (Majority)
- Outpatient management with isolation 2
- Supportive care focusing on symptom relief 7
- Disease typically resolves in 7-10 days without sequelae 7
Severe/Complicated Cases
- Intravenous immunoglobulin should be considered for severe cases 7
- Intensive monitoring for circulatory failure and neurogenic pulmonary edema (main causes of death) 7
- No specific antiviral agents currently approved, though ribavirin and other candidates are under investigation 7
Prevention Strategies
Primary Prevention
- Hand hygiene education for children and caregivers 8
- Breastfeeding promotion (shown to reduce transmission) 8
- Environmental sanitation of shared surfaces and toys
- EV-A71 vaccination in high-risk areas (>90% efficacy against severe disease) 8
Common Pitfalls to Avoid
- Delayed notification of clustered cases beyond 24 hours significantly worsens outbreak control 3
- Underestimating non-EV-A71 serotypes - these cause 35% of severe CNS complications 4
- Missing atypical presentations - CV-A2/CV-A4 may lack classic rash patterns 4
- Inadequate monitoring of children under 3 with disease duration <3 days 2